???pagination.result.count???
???pagination.result.page???
1
Stapled, Long-Acting Xenopus GLP-1-Based Dual GLP-1/Glucagon Receptor Agonists with Potent Therapeutic Efficacy for Metabolic Disease. , Han C, Sun Y, Yang Q, Zhou F, Chen X, Wu L, Sun L, Han J ., Mol Pharm. August 2, 2021; 18 (8): 2906-2923.
Stapled and Xenopus Glucagon-Like Peptide 1 (GLP-1)-Based Dual GLP-1/Gastrin Receptor Agonists with Improved Metabolic Benefits in Rodent Models of Obesity and Diabetes. , Chen X, Fu J, Zhou F, Yang Q, Wang J , Feng H, Jiang W, Jin L, Tang X, Jiang N, Yin J, Han J ., J Med Chem. November 12, 2020; 63 (21): 12595-12613.
Rational design of dimeric lipidated Xenopus glucagon-like peptide 1 analogues as long-acting antihyperglycaemic agents. , Han J , Huang Y, Chen X, Zhou F, Fei Y, Fu J., Eur J Med Chem. September 5, 2018; 157 177-187.
Micellar Nanomedicine of Novel Fatty Acid Modified Xenopus Glucagon-like Peptide-1: Improved Physicochemical Characteristics and Therapeutic Utilities for Type 2 Diabetes. , Han J , Fei Y, Zhou F, Chen X, Zheng W, Fu J., Mol Pharm. November 6, 2017; 14 (11): 3954-3967.
Transient expression of Ngn3 in Xenopus endoderm promotes early and ectopic development of pancreatic beta and delta cells. , Oropeza D, Horb M ., Genesis. March 1, 2012; 50 (3): 271-85.